Preview Mode Links will not work in preview mode

Nov 21, 2019

Breast Cancer Update, Issue 4, 2019 — Part 2: Our interview with Dr Telli highlights the following topics as well as cases from her practice:

  • Case: A woman in her early 50s with de novo metastatic TNBC is enrolled on the IMpassion130 trial evaluating atezolizumab with nab paclitaxel (00:00)
  • Initial workup and genetic testing for patients with metastatic TNBC (02:33)
  • Risk of recurrence for patients with localized TNBC; patterns of metastasis (05:11)
  • Approach to PD-L1 testing for patients with TNBC (07:29)
  • Results of the Phase III IMpassion130 study of atezolizumab with nab paclitaxel for previously untreated advanced TNBC (10:41)
  • Clinical implications of the IMpassion130 study results (14:57)
  • Perspective on progression-free and overall survival outcomes with atezolizumab/nab paclitaxel (16:59)
  • Clinical experience with atezolizumab and nab paclitaxel as first-line therapy for advanced TNBC (19:05)
  • Tolerability of atezolizumab in the IMpassion130 trial (23:52)
  • Activity of single-agent pembrolizumab in patients with TNBC (25:28)
  • Emerging data with pembrolizumab in combination with chemotherapy for TNBC in the (neo)adjuvant setting (27:58)
  • Evaluation of anti-PD-L1 antibodies in the neoadjuvant setting (31:03)
  • Case: A woman in her late 20s with a family history of breast cancer and a germline BRCA mutation receives talazoparib and avelumab on a clinical trial for metastatic TNBC (33:17)
  • Efficacy and tolerability of platinum regimens for patients with TNBC (35:25)
  • Results from the OlympiAD (olaparib) and EMBRACA (talazoparib) trials for patients with HER2-negative advanced breast cancer and a germline BRCA mutation (42:40)
  • Activity and side-effect profile of olaparib versus talazoparib (46:43)
  • Ongoing investigation of the combination of anti-PD-1/PD-L1 antibodies and PARP inhibitors (49:47)
  • Sequencing PARP inhibitors for patients with PD-L1-negative breast cancer (53:03)
  • Use of PARP inhibitors for patients with breast cancer and mutations in DNA damage repair genes beyond BRCA (55:52)
  • Tolerability of PARP inhibitors for patients with germline BRCA mutations (1:00:35)

CME information and select publications